Yüklüyor......
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
BACKGROUND: The European Medicine Agency granted marketing approval to 164 orphan medicinal products for rare diseases, among which 28 products intended for the treatment of hereditary metabolic diseases. Taking advantage of its privileged connection with 69 healthcare centres of excellence in this...
Kaydedildi:
| Yayımlandı: | Orphanet J Rare Dis |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6945588/ https://ncbi.nlm.nih.gov/pubmed/31907071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-019-1280-5 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|